Abstract
IntroductionNS9531, NS9762 and NS6417 are nitroquinolinyl-diazabicyclo-alkane derivatives that have been developed as inhibitors of serotonin reuptake transporters (SERT) by NeuroSearch A/S. MethodsIC50 was measured on the up-take of serotonin, dopamine and noradrenaline in synaptosomes prepared from selected rat brain regions. For the pre-clinical evaluation in pigs, [11C]NS9531, [11C]NS9762 and [11C]NS6417 were prepared by N-methylation using [11C]methyl iodide. These syntheses were later on optimized regarding: 1) choice of labelled precursor; 2) HPLC purification conditions; and 3) formulation using SPE columns. The synthesis protocols were then fully automated on a GE FXc Pro. Preclinical evaluation was performed by PET studies in landrace pigs before and after treatment with citalopram. ResultsIC50 measurements showed that all three compounds have low nanomolar affinity for SERT, and micromolar affinity for DAT and NET. The radiochemical yield (r.y.) of all three ligands from [11C]methyl iodide was higher than 30%. From [11C]methyl triflate, the r.y. of [11C]NS9531 and [11C]NS9762 were higher than 80% whereas the r.y. of [11C]NS6417 was 65%. Residual precursor amounts in final products could be significantly reduced by the use of [11C]methyl triflate, <0.2μg compared with <10μg, calculated for a 300MBq injection at 20minutes EOS. The optimized conditions gave 2.5–4.5GBq of products with a specific radioactivity of 20–70MBq/nmol, residual acetonitrile 15–30ppm, and pH6.5–7.1. All three compounds showed a rapid and comparable high pig brain uptake of about 3%, producing PET images of good contrast, and uptake was reduced after pre-administration with citalopram. ConclusionThe three 11C labelled PET tracers could be prepared in medium to high yield and high purity. IC50 measurements showed that the three NS compounds were highly selective, high affinity SERT inhibitors. PET studies in pig showed high brain uptake that could be blocked by citalopram pre-treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.